CAS: 432037-57-5; (Z)-4-(3-(6-(4-Chlorophenoxy)Hexyl)-2-Cyanoguanidino)-1-(3-Oxo-2,4,7,10,13,16-Hexaoxaheptadecyl)Pyridin-1-Ium
该化合物是一个复杂的有机化合物,其特点是其复杂的分子结构.它具有多种醚联系,有助于其溶解性和在各种化学环境中的潜在应用. 存在一种的微生物表明,它可能表现出化学特性,使其适合与厌离物种的相互作用. 此外,Guanidinino组表明潜在的生物活动,有可能影响其在药用中的作用. 氯苯氧组可能增强其脂性,促进膜的渗透性.
- 英文名称(Z)-4-(3-(6-(4-Chlorophenoxy)Hexyl)-2-Cyanoguanidino)-1-(3-Oxo-2,4,7,10,13,16-Hexaoxaheptadecyl)Pyridin-1-Ium
- 中文名称1-[[[[2-[2-[2-[2-甲氧基乙氧基]乙氧基]乙氧基]乙氧基]羰基]氧基]甲基]-4-[N’-氰基-N’’-[6-[4-氯苯氧基]己基]胍基]氯化吡啶
- IUPAC名称(Z)-4-(3-(6-(4-chlorophenoxy)hexyl)-2-cyanoguanidino)-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadecyl)pyridin-1-ium
- 其它别名Pyridinium, 4-((((6-(4-Chlorophenoxy)Hexyl)Imino)(Cyanoamino)Methyl)Amino)-1-(3-Oxo-2,4,7,10,13,16-Hexaoxaheptadec-1-yl)-, Chloride (1:1); Teglarinad Chloride [usan:Inn]; [4-[[n'-[6-(4-Chlorophenoxy)Hexyl]-N-Cyanocarbamimidoyl]Amino]Pyridin-1
- CAS编号432037-57-5
- MFCD编号:MFCD16038864
- FDA UNII编号:D6V5QYX9MZ
- 分子式:C30H43ClN5O8分子量:637.15
- 产品CID: 1443784
- 同类组份化合物CAS766501-75-1 (cation)432037-57-5 (chloride)
- 产品分类医药中间体 → 吡啶类化合物
物理性质
- 熔点158-159 °C
- 沸点158-159°C
- PSA:147.15
- LogP:5.10808
- 溶解性DMSO: 200 mg/mL (297.35 Mm)
- 外观形态白色至类白色固体
- 储存条件-20°C，干燥环境，密封保存
- 产品应用该化合物是GM X1778的一种抗药剂,一种硝基丁胺磷酸磷基转移酶抑制剂(NAMPT),通过NAPT抑制剂在小鼠中表现出抗突触活动;它通过干扰DNA修复和产生抗血管效应,提高放射疗法的功效;它诱发多种色素脱氧模型的肿瘤回归,包括IM-9多细胞血浆,小细胞肺癌(SHP-77)和结肠癌(HCT-116),它显示出对活体中的FADU和C666-1肿瘤的重大抗菌活动,两者都是单一疗法,并与当地肿瘤放射疗法相结合.
MSDS等安全信息
合成工艺路线路线简述
📜Chloromethyl 2-(2-(2-(2-Methoxyethoxy)Ethoxy)Ethoxy)Ethyl Carbonate置于sodium Iodide体系中,用 丙酮,乙腈 作为反应溶剂,化学反应 0.33H,反应生成 1-[[[[2-[2-[2-[2-甲氧基乙氧基]乙氧基]乙氧基]乙氧基]羰基]氧基]甲基]-4-[n'-氰基-N''-[6-[4-氯苯氧基]己基]胍基]氯化吡啶
参考文献:Eb1627: A Soluble Prodrug Of The Potent Anticancer Cyanoguanidine Chs828
标题:Eb1627: A Soluble Prodrug Of The Potent Anticancer Cyanoguanidine Chs828
摘要:To Overcome Pharmacokinetic And Solubility Problems Observed In Early Clinical Trials With The Potent Anticancer Compound Chs828,We Synthesised A Series Of Prodrugs With Improved Properties. The Best Compound Obtained Was Eb1627,With A Tetraethyleneglycol Moiety Attached To The Parent Drug Via A Carbonate Linkage. This Compound Was Found Soluble Enough To Be Given I.V. And The Drug Was Rapidly Released In Vivo Exerting A Very Potent Inhibitory Activity Alone And In Combination With Known Cytostatics (Etoposide) In Animal Models In Vivo. (C) 2005 Elsevier Ltd. All Rights Reserved.
DOI:10.1016/j.Bmcl.2005.03.064
海关参考信息
- 2903919090-氯苯
2905121000-正丙醇
2905130000-正丁醇
2905310000-1,2-乙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12336981-B2
优先权日:2010-09-03
标题 :Compounds and compositions for the inhibition of NAMPT
发明人：BAIR KENNETH W; BAUMEISTER TIMM R; BUCKMELTER ALEXANDRE J; CLODFELTER KARL H; DRAGOVICH Peter; GOSSELIN FRANCIS; HAN BINGSONG; LIN JIAN; REYNOLDS DOMINIC J; ROTH BRUCE; SMITH CHASE C; WANG ZHONGGUO; YUEN PO-WAI; ZHENG XIAOZHANG
权利人:VALO HEALTH INC; GENENTECH INC
摘要:The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:
专利号:US-11279687-B2
优先权日:2010-09-03
标题:Compounds and compositions for the inhibition of NAMPT
发明人：BAIR KENNETH W; BAUMEISTER TIMM R; BUCKMELTER ALEXANDRE J; CLODFELTER KARL H; HAN BINGSONG; LIN JIAN; REYNOLDS DOMINIC J; SMITH CHASE C; WANG ZHONGGUO; ZHENG XIAOZHANG; YUEN PO-WAI
权利人:VALO HEALTH INC; GENENTECH INC
摘要:The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An embodiment of the invention is the provision of a compound of Formula IIIA.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Preyat N, Leo O. Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways. Biochem Pharmacol. 2016 Feb 1;101:13-26. doi: 10.1016/j.bcp.2015.08.110. Epub 2015 Sep 3. doi: 10.1158/0008-5472.CAN-14-0809. Epub 2014 Aug 21. doi: 10.1186/1471-2407-10-677.
4: Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther. 2010 Jul 15;10(2):119-25. doi: 10.4161/cbt.10.2.12581. Epub 2010 Jul 3. Review. doi: 10.1002/ijc.25206. doi: 10.1158/1078-0432.CCR-09-1945. Epub 2010 Jan 26. doi: 10.1128/MCB.00112-09. Epub 2009 Aug 24.
8: Beauparlant P, Bédard D, Bernier C, Chan H, Gilbert K, Goulet D, Gratton MO, Lavoie M, Roulston A, Turcotte E, Watson M. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs. 2009 Jun;20(5):346-54. doi: 10.1097/CAD.0b013e3283287c20.
合成参考文献
参考文献:10.1158/0008-5472.can-14-0809
摘要:Chan M, Gravel M, Bramoullé A, Bridon G, Avizonis D, Shore GC, Roulston A. Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption. Cancer Res. 2014 Nov 01;74(21):5948–54. doi: 10.1158/0008-5472.can-14-0809.
参考文献:10.1007/978-3-032-00771-1_269
摘要:Helman T, Braidy N. NAD+ as a Target for Cancer Treatment. 2025. In: Handbook of Cancer and Immunology.
参考文献:10.1016/j.bmcl.2005.03.064
摘要:Binderup E, Björkling F, Hjarnaa PV, Latini S, Baltzer B, Carlsen M, Binderup L. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. Bioorganic & Medicinal Chemistry Letters. 2005 May;15(10):2491–4. doi: 10.1016/j.bmcl.2005.03.064.
📝 需求与反馈
尽可能描述清楚需求与问题信息
